NYSE American Listing Standards - Unrestricted Publicly-Held Shares Requirements

The SEC published notice and approved NYSE American's proposed rule change to amend Sections 101 and 102 of the NYSE American Company Guide. The Exchange will now calculate market value of publicly-held shares using only unrestricted publicly-held shares, excluding securities subject to resale restrictions such as private placements, employee stock plans, and lockup agreements. The Exchange also added new definitions for Restricted Securities, Publicly-Held Shares, Unrestricted Securities, and Unrestricted Publicly-Held Shares.

Cboe EDGA Exchange Clock Service Rule Change

The SEC published notice on March 26, 2026 of Cboe EDGA Exchange's proposed rule change to amend Rule 13.8 to establish a new optional Clock Service. The service would allow Members and non-Members to synchronize their time recording systems to the Exchange's primary clock for precise latency measurements. The proposal responds to participant demand for enhanced time synchronization options and is similar to services offered by other exchanges like MIAX Emerald.

Visceral epicardial adipose tissue atherosclerosis risk study

The National Library of Medicine registered clinical trial NCT07504679 on ClinicalTrials.gov. The trial, titled 'Visceral epicardial adipose tissue atherosclerosis risk study,' is investigating the relationship between visceral epicardial adipose tissue and atherosclerosis risk. Clinical trial registrations on ClinicalTrials.gov are informational records maintained under NIH authority.

Phase 1 trial 177Lu-IM-3050 radiopharmaceutical advanced solid malignancies

The National Library of Medicine registered a new Phase 1 clinical trial (NCT07505771) on ClinicalTrials.gov evaluating 177Lu-IM-3050 radiopharmaceutical in patients with advanced solid malignancies. The dose-escalation study represents an informational registry entry documenting ongoing clinical research activity.

Clinical trial NCT07506395 page content retrieval error

ClinicalTrials.gov, operated by the National Library of Medicine, reported that page content for clinical trial NCT07506395 could not be fully retrieved. This is a system-level notification indicating incomplete data retrieval rather than a regulatory document or enforcement action.

HER2 trial, trastuzumab serplulimab, biliary urothelial cancer

National Cancer Institute registered a Phase 2 clinical trial (NCT07506057) on ClinicalTrials.gov evaluating trastuzumab combined with serplulimab for HER2-positive biliary urothelial cancer. The study is sponsored by National Cancer Institute investigators and will assess safety and efficacy of this novel combination therapy in approximately 40 patients.

Ofatumumab Multiple Sclerosis Real-World Experience Study

NIH National Library of Medicine registered a new observational study on ClinicalTrials.gov examining real-world use of ofatumumab in multiple sclerosis patients. The study (NCT07504783) will collect data on treatment outcomes and patient experiences outside controlled clinical trial settings. Trial sponsors must register qualifying clinical trials on ClinicalTrials.gov under FDAAA 801 requirements.

Transcranial alternating current stimulation frontotemporal dementia trial, Italy

ClinicalTrials.gov registered a new interventional study (NCT07505784) evaluating transcranial alternating current stimulation (tACS) for frontotemporal dementia. The single-center trial is conducted in Italy. Registration was posted to the public ClinicalTrials.gov registry.

Sinovac Phase III meningococcal vaccine trial, children 12-23 months

Sinovac Phase III meningococcal vaccine trial, children 12-23 months

Distributed Encrypted Data System with Hash Verification

The European Patent Office published Patent EP4179693A1, filed by International Business Machines Corporation, covering a method and system for distributing encrypted data objects with hash verification. The invention enables verification of data integrity during encrypted data transmission. The patent application was published March 25, 2026.